Ï Ä.Ì. åîïìïëïãåßôáé...

Boy Ç éóôïñßá ìïõ åßíáé ëßãï-ðïëý ßäéá ìå áñêåôþí üóùí Ý÷ïõí ãñÜøåé åäþ.

¸÷ïõìå ðïëëÜ êïéíÜ. Êé åãþ êÜðùò Ýôóé óêÝöôçêá íá ãñÜøù ôç äéêÞ ìïõ éóôïñßá.

Åßìáé 26 ÷ñïíþí êáé Ýìáèá ðùò åßìáé ïñïèåôéêüò ìüëéò ðñéí áðü ìéá åâäïìÜäá.

Ìéá öïñÜ áðåñéóêåøßáò Þôáí áñêåôÞ ãéá íá ôçí ðáôÞóù êáé ãéá üóïõò ðéóôåýïõí üôé åäþ óôçí ÅëëÜäá äåí êéíäõíåýåéò ðïëý, Ý÷ù íá ðù ðùò åãþ ôï Ýðáèá öõóéêÜ åäþ. ÐïõèåíÜ áëëïý.

Ôçí ðÜôçóá ìå ìüíï ìéá öïñÜ ÷ùñßò ðñïöõëáêôéêü, ìå Ýíáí ðïëý ìéêñüôåñü ìïõ óôçí çëßêéá. ÊÜðïéïé ößëïé ìïõ åß÷áí ðåé ôüôå üôáí ôïõò åéðá ðùò Ýêáíá ìáëáêéá êáé ôïí Üöçóá íá êÜíïõìå óåî ÷ùñßò ðñïöõëáêôéêü: «¢íôå ñå, ìçí áíçóõ÷åßò. Áõôü åßíáé ó÷åäüí ìùñü áêüìá...».
Ðïëëïß èåùñïýí ðùò åßíáé èÝìá çëéêéáò êáé üôé áí ðáò ìå êÜðïéïí ìéêñüôåñï, äåí Ý÷åéò öüâï.

¸êáíá ôñßá åðáíáëçðôéêÜ ôåóô ìÝ÷ñé ôåëéêÜ íá äéáðéóôþóù üôé Ý÷ù ìïëõíèåß ìå ôïí HIV.
Óôï éäéùôéêü åñãáóôÞñéï üðïõ Ýêáíá ôçí ðñþôç åîÝôáóç ãéá HIV Þôáí ðïëý äéáêñéôéêïß. Ìïõ åßðáí üôé ôï áðïôÝëåóìá Þôáí ïñéáêÜ èåôéêü êáé üôé ÷ñåéáæüôáí áðáñáßôçôá åðéâåâáßùóç.
Ôþñá ðüóï ïñéáêü Þ îåêÜèáñï Þôáí, Ýíáò Èåüò ôï îÝñåé.

Óôï äçìüóéï íïóïêïìåßï üðïõ ìå Ýóôåéëáí ãéá ðåñáéôÝñù åîåôÜóåéò, ïé íïóïêüìåò êÜèå öïñÜ ðïõ ìå êïßôáãáí Þôáí óáí íá ìïõ ôï óéãïõñåýïõí.

¸êáíáí íåýìáôá ðïõ êáé êáëÜ íüìéæáí üôé äåí Ýâëåðá.
ØéèõñéóôÝò óõíïìéëßåò ôçí þñá ðïõ ðåñéìåíá. ÊÜðïéïé óõíáäåëöïß ôïõò ðïõ Ýâãáéíáí íá äïõí êáé êáëÜ áí êïõíéïýíôáé ïé âÜñêåò.
Äåí Þîåñá åáí Ýðñåðå íá êëÜøù Þ íá ãåëÜóù ìå áõôÞ ôçí êáôÜóôáóç.
Áðü ôçí Üëëç âÝâáéá ìðïñåß üðïéïò Ý÷åé ôç ìýãá íá ìõãéÜæåôáé, üðùò ëÝíå...

Ìüëéò Ýêáíá ôï äåýôåñï ôåóô ãéá HIV, Üñ÷éóá íá øÜ÷íù óôï ßíôåñíåô ðëçñïöïñßåò ãéá ôï AIDS áëëÜ äõóôõ÷þò äåí âñÞêá ðïëëÝò ó÷åôéêÝò éóôïóåëßäåò áðü ÅëëÜäá, ïðüôå Ýöôáóá ãñÞãïñá óå áõôÞí åäþ.

Eßìáé áñêåôÜ áéóéüäïîïò êáé åëðßæù ïôé áõôÜ ðïõ èÝëù íá êÜíù óôï ìÝëëïí, èá êáôáöÝñù ôåëéêÜ íá ôá êÜíù. ¸óôù êáé áí ðáñïõóéáóôïýí êÜðïéåò äõóêïëßåò óôï ìÝëëïí ëüãù ôçò áóèÝíåéÜò ìïõ.

¹èåëá íá ðù ðùò ôï íá åßìáé óå ìéá ó÷åôéêÜ Þñåìç øõ÷ïëïãéêÞ êáôÜóôáóç - ïýôå ðïëý êáëÜ, áëëÜ ïýôå êáé ðïëý óôåíá÷ùñçìÝíïò ìå êëÜììáôá êáé ôÝôïéá (åêôüò ôçò ðñþôçò ìÝñáò ðïõ ôï Ýìáèá) - âïÞèçóáí ïé éóôïñßåò ðïõ äéÜâáóá åäþ.

Íéþèù üôé åßìáé äõíáôüò ãéá íá ôï áíôéìåôùðßóù êáé åëðßæù ðùò ìå ôçí âïÞèåéá ôùí ãéáôñþí, üëá èá ðÜíå êáëÜ.

Ç æùç óõíå÷ßæåôáé... óôï ìÜîéìïõì!




... 'Aëëåò éóôïñßåò ...

+/-
ÌÜèå ôï status óïõ

Âñåò ôï ãéáôñü óïõ

ÐÜñå èåñáðåßá

¸ëåãîå ôï ééêü óïõ öïñôßï

Ôåëåõôáßåò åéäÞóåéò

21/2/2017
News : Ôï ÊÅÅËÐÍÏ óå ×ßï êáé ÌõôéëÞíç ãéá ôç äéá÷åßñéóç ðåñéóôáôéêþí HIV óôéò ðñïóöõãéêÝò äïìÝò. Ï ðñüåäñïò ôïõ ÊÅÅËÐÍÏ, áíáðëçñùôÞò êáèçãçôÞò Èåüöéëïò Ñüæåíìðåñãê, áíáêïéíþóå ôçí áðïóôïëÞ äéåðéóôçìïíéêïý êëéìáêßïõ ôïõ Ïñãáíéóìïý åíôüò ôùí åðüìåíùí çìåñþí, óôá äýï íçóéÜ. Ðñïò ôï óêïðü ôçò ðñïÜóðéóçò ôçò äçìüóéáò õãåßáò, ôï êëéìÜêéï ôïõ ÊÅÅËÐÍÏ èá åðéêåíôñùèåß óôçí åíçìÝñùóç ôùí åðáããåëìáôéþí õãåßáò ãéá ôçí ïñèÞ äéá÷åßñéóç ôùí ðåñéóôáôéêþí HIV óôïí ðñïóöõãéêü/ìåôáíáóôåõôéêü ðëçèõóìü êáé óôçí áãùãÞ õãåßáò óôçí êïéíüôçôá êáé ôçí øõ÷ïêïéíùíéêÞ óôÞñéîç.
14/2/2017
News : Èåóóáëïíßêç: ÄùñåÜí ôåóô ãéá HIV, çðáôßôéäåò  êáé C óÞìåñá. Ç ÌÊÏ PRAKSIS êáé ôï ÊÝíôñï ÆùÞò ãéïñôÜæïõí ôç ìÝñá ôïõ Áãßïõ Âáëåíôßíïõ óôçí ÊáìÜñá ìå äñÜóåéò åíçìÝñùóçò, ðñüëçøçò êáé åîÝôáóçò. ÓôåëÝ÷ç ôçò PRAKSIS ìå ôçí ÊéíçôÞ ÌïíÜäá ÅîÝôáóçò èá âñåèïýí ôçí Ôñßôç 14 Öåâñïõáñßïõ, áðü ôéò 18.00 Ýùò êáé ôéò 22.00 óôçí ÊáìÜñá ðáñÝ÷ïíôáò ôç äõíáôüôçôá íá åíçìåñþóïõí ôïõò ðïëßôåò ãéá ôïí HIV êáé ãéá ôéò Çðáôßôéäåò, åíèáññýíïíôáò ôïõò ðáñÜëëçëá íá åîåôáóôïýí äùñåÜí, áíþíõìá êáé ãñÞãïñá. Ç åîÝôáóç áöïñÜ üëá ôá Üôïìá ðïõ Ý÷ïõí åíåñãÞ óåîïõáëéêÞ æùÞ.
9/2/2017
News : Ôï ABX464 åßíáé Ýíá ìïíáäéêü áíôé-ééêü óýìðëåãìá ìéêñþí ìïñßùí ðïõ óôï÷åýïõí ôçí RNA âéïãÝíåóç. Áõôü ôï ìüñéï åßíáé ôï ðñþôï óôçí êáôçãïñßá ôïõ ìå ìïíáäéêÝò éäéüôçôåò êáé ôñüðï äñÜóçò. ÓõãêåêñéìÝíá, áíáóôÝëëåé ôçí ðñùôåÀíç REV HIV, ç ïðïßá åßíáé êñßóéìç ãéá ôçí áíôéãñáöÞ ôïõ HIV. Ôï ABX464 áíáóôÝëëåé in vitro êáé in vivo ôçí áíôéãñáöÞ ôïõ éïý êáé ðñïêáëåß ìáêñü÷ñïíç ìåßùóç ôïõ ééêïý öïñôßïõ ìåôÜ ôç äéáêïðÞ ôçò èåñáðåßáò óå Ýíá ðñïêëéíéêü ìïíôÝëï ôïõ HIV. Óõíåðþò, ôï ABX464 ìðïñåß íá åßíáé ç ðñþôç áíÜðôõîç ìéáò ëåéôïõñãéêÞò èåñáðåßáò ãéá ôï HIV

Ôï video ôçò çìÝñáò

Video

Æþíôáò ìå ôï óôßãìá ôïõ HIV

Äçìïóéåýèçêå óôéò 2015-11-24

¸îé ïñïèåôéêÜ Üôïìá ìéëïýí ãéá ôï óôßãìá ðïõ áíôéìåôùðßæïõí êáèçìåñéíÜ ëüãù ôçò áóèÝíåéÜò ôïõò.



Lancet

Ðñüóöáôåò äçìïóéåýóåéò óôï ðåñéïäéêü The Lancet HIV

Anti-inflammatory therapy in well controlled HIV infection

In The Lancet HIV, the ADVICE study group1 report the results of the ADVICE study, which aimed to study the effect of vorapaxar in reducing deleterious pro-inflammatory and pro-coagulatory mechanisms in patients with well controlled HIV infection. Vorapaxar is an anticoagulatory drug that inhibits thrombin-induced platelet aggregation, and has not previously been studied in HIV.2 Vorapaxar is an antagonist of proteinase-activated receptor 1 (PAR-1), and findings from previous studies suggest that PAR-1 is upregulated by CD4 and CD8 cells, even in well suppressed HIV infection.

HIV care continuum for key populations in Indonesia

The HIV epidemic remains largely concentrated among key populations in countries across the Asia-Pacific region, including Indonesia. Key populations at high risk are people who inject drugs (PWID), men who have sex with men (MSM), female sex workers, and transgender people (known as waria in Indonesia). HIV testing and treatment in these groups are low in the region.1 Engagement of HIV-positive individuals at each stage of the HIV care continuum is crucial for positive outcomes. The continuum, which includes diagnosis, linkage to and retention in HIV care, prescription of antiretroviral therapy (ART), and viral suppression, reduces mortality and morbidity and prevents further HIV transmission.

No more Scott Counties

The opioid crisis in the USA has caused enormous suffering and the loss of hundreds of thousands of lives, and in 2017 surpassed motor vehicle accidents as a cause of death in the USA.1 In 2017 alone, of 72 000 estimated deaths resulting from overdose, more than 63 000 were due to opiates,2 exceeded the number of US military personnel who died during the Vietnam war (about 58 000 people).3 The greatest number of people who died of drug overdoses were Americans aged 24–35 years. In 2016, one in five deaths in this vital age group involved opioids.

About us

Óôï hivaids.gr, öéëïîåíïýìå áöéëïêåñäþò ôï "Ðñüãñáììá Óõíåñãáóßáò" ÌïíÜäùí Ëïéìþîåùí ãéá ôçí áíÜðôõîç äéáäéêôõáêÞò ôñÜðåæáò êëéíéêþí ðáñáìÝôñùí. Ôï Ðñüãñáììá äçìéïõñãÞèçêå áðü Ýíáí ãéáôñü åéäéêü óôçí HIV ëïßìùîç ìå ôç óõììåôï÷Þ ôùí ÌïíÜäùí: Ðåñéóóüôåñá

% Áíáðçñßá êáé HIV

ÍÝïò êáíïíéóìüò

Åíéáßïò Ðßíáêáò Ðñïóäéïñéóìïý Ðïóïóôïý Áíáðçñßáò

Çìåñïëüãéï

@ Äéáýãåéá

ÄéáýãåéáÄé@ýãåéá

äéáöÜíåéá óôï êñÜôïò

ÄéáäéêôõáêÝò áíáñôÞóåéò äéïéêçôéêþí áðïöÜóåùí ãéá ôï HIV/AIDS

Twitter

¸ñåõíá

Óáò Ý÷åé óðÜóåé ðïôÝ ôï ðñïöõëáêôéêü êáôÜ ôç äéÜñêåéá ìéáò åñùôéêÞò åðáöÞò;
Íáé
¼÷é
Äåí ÷ñçóéìïðïéþ

Åðéêïéíùíßá

Newsletter

Áíáêïéíþóåéò

×ñÞóéìåò ðëçñïöïñßåò